PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Journals
More Content
PLOS BLOGS Speaking of Medicine and Health
Browse all PLOS Blogs
Browse all PLOS Blogs

PLOS Pathogens’ COVID-19 response

PLOS Guest Blogger Covid-19 Editorial Global Health Open Access Pandemic Pathogens Vaccines

Michael Malim and *Kasturi Haldar, Editors-in-Chief of PLOS Pathogens, share the journal’s plan to accelerate and amplify COVID-19 research.

Open and readily available research

This is a time of great challenges and great opportunities for scientists and clinicians working on COVID-19. PLOS Pathogens is committed to building and communicating a robust knowledge base for present and future research that will benefit patients and society.  We publish the latest discoveries in SARS-CoV-2 research, including reports of novel research, in depth Reviews, and shorter Pearls and Opinion pieces. As an Open Access journal, these articles and the underlying data are available to read and cite immediately. This is of paramount importance to ensure these advances can be read and built upon right from the start.

Expert and accelerated editorial oversight

We have entrusted a team of editors who are leading experts in the field, comprised of:

  • Michael Diamond, MD, PhD, Washington University School of Medicine in St. Louis
  • Ron Fouchier, PhD, Erasmus University Medical Center
  • Benhur Lee, MD, Icahn School of Medicine at Mount Sinai
  • Andrew Pekosz, PhD, Johns Hopkins Bloomberg School of Public Health
  • Kanta Subbarao, MBBS, MPH, The Peter Doherty Institute for Infection and Immunity
  • David Wang, PhD, Washington University School of Medicine in St. Louis

This team is committed to accelerating the time to both review and publication. We strive to make an initial editorial decision (reject or review) within three days of editor assignment.

PLOS Pathogens provides a perfect home for your SARS-CoV-2 research

PLOS Pathogens welcomes submissions on the full range of COVID-19 research, including: virology, structural biology, evolution, host interactions, immune responses, pathogenesis, co-morbidities, diagnostics, public health & infection control, vaccines, drug discovery, and clinical trials.

The PLOS-wide COVID-19 collection contains all published COVID-19 research from the full PLOS portfolio. PLOS Pathogens articles will be added to this page upon publication, so papers are accessible across all disciplines.

Learn how to submit.

Mike Diamond
Andy Pekosz
Kanta Subbarao
David Wang
Benhur Lee
Ron Fouchier

Image by Pete Linforth from Pixabay

*Updated note: Dr. Kasturi retired from the journal in November 2023

Related Posts
Back to top